News | Proton Therapy | September 17, 2019

IBA Gathers Experts on Flash Irradiation During ASTRO

Key opinion leaders in the field of proton therapy shared their latest insights and research on Flash irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on proton therapy

IBA Gathers Experts on Flash Irradiation During ASTRO

September 17, 2019 — IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.

In addition, during IBA’s annual symposium on proton therapy, Amit Maity, M.D., executive vice-chair radiation oncology, Perelman School of Medicine, University of Pennsylvania, also shared the latest insight on proton Flash radiation therapy for gastrointestinal (GI) malignancies.  

Flash therapy has the potential to dramatically change the landscape of radiotherapy and patient cancer care, making it more effective and more accessible than conventional radiotherapy. Flash irradiation is a fast and powerful treatment that delivers a high dose of radiation at an ultra-high dose rate. This novel technique could potentially shorten treatment time from 6-8 weeks to less than a week, and has the potential to reduce side effects for patients.

IBA is collaborating with several leading proton therapy centers in their research work to better understand the mechanisms of Flash irradiation. This early development work enables IBA today to deliver Flash irradiation on both its current single- and multi-room proton therapy platforms in a clinical environment in research mode, as demonstrated in March 2019 at the University Medical Center of Groningen, The Netherlands, and in June 2019 at the Rutherford Cancer Center Thames Valley in Reading, England. 

Alexander Lin, M.D., associate professor of radiation oncology and chief of the Head and Neck Oncology Service at the Hospital of the University of Pennsylvania, Philadelphia, commented, “Flash is a very exciting opportunity and we believe that proton therapy can be a very suitable modality to achieve the desired outcomes. We are at a stage where more research is needed to better understand the mechanisms of FLASH irradiation, and we are very excited about our current research program at Penn Medicine. Coordinating our efforts with other centers is key, and IBA’s Victoria meeting offered a great forum to share our insights.”

Flash therapy is currently under research and is not available for sale.

For more information: www.iba-worldwide.com

Related Content

Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit